Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.59 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 6/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065929 | 0.88 | RIPK1 (0.60) | RIPK1TBK1BTKEGFRWDR5 | |
| SCHEMBL4062847 | 0.84 | RIPK1 (0.58) | RIPK1TBK1MAPKAPK2BTKCSF1R | |
| SCHEMBL4773340 | 0.82 | NPC1 (0.53) | RIPK1TBK1BTKCSF1REGFR | |
| SCHEMBL16809667 | 0.82 | TBK1 (0.60) | RIPK1TBK1BTKCSF1R | |
| SCHEMBL16793805 | 0.80 | TBK1 (0.60) | RIPK1TBK1MAPKAPK2BTKCSF1R | |
| SCHEMBL20150991 | 0.79 | EGFR (0.53) | RIPK1TBK1BTKCSF1RJAK2 | |
| SCHEMBL4465947 | 0.79 | HDAC3 (0.58) | RIPK1CSF1REGFR | |
| SCHEMBL4068131 | 0.78 | RIPK1 (0.57) | RIPK1TBK1BTKEGFR | |
| SCHEMBL4473017 | 0.78 | RIPK1 (0.57) | RIPK1TBK1BTKCSF1REGFR | |
| SCHEMBL28129363 | 0.77 | TBK1 (0.68) | RIPK1TBK1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625894-B2 | Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | claimed |
| EP-1718651-B1 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | claimed |
| EP-1718651-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2006-11-08 | — | — | EP | claimed |
| WO-2005077951-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | claimed |
| US-7625894-B2 | Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| EP-1718651-B1 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | disclosed |
| EP-1718651-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005077951-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | DPYD, TYMP, DHPS | RIPK1 3871/4885TBK1 2979/4885MAPKAPK2 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.